Last reviewed · How we verify
CNP-103
At a glance
| Generic name | CNP-103 |
|---|---|
| Also known as | Treatment |
| Sponsor | COUR Pharmaceutical Development Company, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CNP-103 CI brief — competitive landscape report
- CNP-103 updates RSS · CI watch RSS
- COUR Pharmaceutical Development Company, Inc. portfolio CI